Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(9):1492–1498. doi: 10.1038/bjc.1996.571

Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.

E W Steyerberg 1, H J Keizer 1, S D Fosså 1, D T Sleijfer 1, D F Bajorin 1, J P Donohue 1, J D Habbema 1
PMCID: PMC2074767  PMID: 8912551

Abstract

Residual retroperitoneal masses may remain after chemotherapy for metastatic non-seminomatous testicular cancer, which harbour residual tumour or totally benign tissue (necrosis/fibrosis). These residual masses may be effectively removed by a surgical resection. We evaluated current selection criteria and tried to develop alternative criteria in a data set of 544 patients, who had retroperitoneal lymph node dissection of residual masses. Six resection policies were identified from the literature. Two alternative policies were developed with logistic regression analysis. Evaluation of the policies focused on the true-positive rate (resection in case of tumour), and the false-positive rate (resection in case of necrosis). It appeared that most current policies use the size of the residual mass (> or = 10 mm or > or = 20 mm) as the predominant selection criterion. This resulted in high true-positive rates (most > 90%), but false-positive rates between 37% and 87%. The alternative policies included five well-known predictors of necrosis in addition to residual mass size (primary tumour histology, prechemotherapy levels of the three tumour markers alphafetoprotein (AFP), human chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) and mass shrinkage during chemotherapy). This strategy resulted in improved true- and false-positive rates, even when categories of the predictors were simplified for practical application. We conclude that a simple statistical model, based on a limited number of patient characteristics, provides better guidelines for patient selection than those currently used in clinical practice.

Full text

PDF
1492

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aass N., Klepp O., Cavallin-Stahl E., Dahl O., Wicklund H., Unsgaard B., Baldetorp L., Ahlström S., Fosså S. D. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol. 1991 May;9(5):818–826. doi: 10.1200/JCO.1991.9.5.818. [DOI] [PubMed] [Google Scholar]
  2. Begg C. B., Greenes R. A. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983 Mar;39(1):207–215. [PubMed] [Google Scholar]
  3. Brown P. D., Bloxidge R. E., Stuart N. S., Gatter K. C., Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993 Apr 7;85(7):574–578. doi: 10.1093/jnci/85.7.574. [DOI] [PubMed] [Google Scholar]
  4. Chirivi R. G., Garofalo A., Crimmin M. J., Bawden L. J., Stoppacciaro A., Brown P. D., Giavazzi R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994 Aug 1;58(3):460–464. doi: 10.1002/ijc.2910580326. [DOI] [PubMed] [Google Scholar]
  5. D'Errico A., Garbisa S., Liotta L. A., Castronovo V., Stetler-Stevenson W. G., Grigioni W. F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol. 1991 Mar;4(2):239–246. [PubMed] [Google Scholar]
  6. Davies B., Brown P. D., East N., Crimmin M. J., Balkwill F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993 May 1;53(9):2087–2091. [PubMed] [Google Scholar]
  7. Donohue J. P., Rowland R. G., Kopecky K., Steidle C. P., Geier G., Ney K. G., Einhorn L., Williams S., Loehrer P. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987 Jun;137(6):1176–1179. doi: 10.1016/s0022-5347(17)44439-9. [DOI] [PubMed] [Google Scholar]
  8. Einhorn L. H. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990 Nov;8(11):1777–1781. doi: 10.1200/JCO.1990.8.11.1777. [DOI] [PubMed] [Google Scholar]
  9. Einhorn L. H., Williams S. D., Mandelbaum I., Donohue J. P. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer. 1981 Aug 15;48(4):904–908. doi: 10.1002/1097-0142(19810815)48:4<904::aid-cncr2820480407>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  10. Fosså S. D., Aass N., Ous S., Høie J., Stenwig A. E., Lien H. H., Paus E., Kaalhus O. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol. 1989 Nov;142(5):1239–1242. doi: 10.1016/s0022-5347(17)39044-4. [DOI] [PubMed] [Google Scholar]
  11. Fosså S. D., Ous S., Lien H. H., Stenwig A. E. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol. 1989 Mar;141(3):557–559. doi: 10.1016/s0022-5347(17)40892-5. [DOI] [PubMed] [Google Scholar]
  12. Fosså S. D., Qvist H., Stenwig A. E., Lien H. H., Ous S., Giercksky K. E. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992 Apr;10(4):569–573. doi: 10.1200/JCO.1992.10.4.569. [DOI] [PubMed] [Google Scholar]
  13. Fox E. P., Weathers T. D., Williams S. D., Loehrer P. J., Ulbright T. M., Donohue J. P., Einhorn L. H. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993 Jul;11(7):1294–1299. doi: 10.1200/JCO.1993.11.7.1294. [DOI] [PubMed] [Google Scholar]
  14. Gelderman W. A., Koops H. S., Sleijfer D. T., Oosterhuis J. W., Oldhoff J. Treatment of retroperitoneal residual tumor after PVB chemotherapy of nonseminomatous testicular tumors. Cancer. 1986 Oct 1;58(7):1418–1421. doi: 10.1002/1097-0142(19861001)58:7<1418::aid-cncr2820580706>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  15. Gelderman W. A., Schraffordt Koops H., Sleijfer D. T., Oosterhuis J. W., Van der Heide J. N., Mulder N. H., Marrink J., De Bruyn H. W., Oldhoff J. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin-vinblastine-bleomycin chemotherapy. J Surg Oncol. 1988 Aug;38(4):227–232. doi: 10.1002/jso.2930380405. [DOI] [PubMed] [Google Scholar]
  16. Gerl A., Clemm C., Schmeller N., Dienemann H., Lamerz R., Kriegmair M., Wilmanns W. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol. 1995 May;6(5):483–488. doi: 10.1093/oxfordjournals.annonc.a059219. [DOI] [PubMed] [Google Scholar]
  17. Harding M. J., Brown I. L., MacPherson S. G., Turner M. A., Kaye S. B. Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1689–1694. doi: 10.1016/0277-5379(89)90336-2. [DOI] [PubMed] [Google Scholar]
  18. Harrell F. E., Jr, Califf R. M., Pryor D. B., Lee K. L., Rosati R. A. Evaluating the yield of medical tests. JAMA. 1982 May 14;247(18):2543–2546. [PubMed] [Google Scholar]
  19. Hendry W. F., A'Hern R. P., Hetherington J. W., Peckham M. J., Dearnaley D. P., Horwich A. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol. 1993 Feb;71(2):208–213. doi: 10.1111/j.1464-410x.1993.tb15920.x. [DOI] [PubMed] [Google Scholar]
  20. Hilden J. The area under the ROC curve and its competitors. Med Decis Making. 1991 Apr-Jun;11(2):95–101. doi: 10.1177/0272989X9101100204. [DOI] [PubMed] [Google Scholar]
  21. Jansen R. L., Sylvester R., Sleyfer D. T., ten Bokkel Huinink W. W., Kaye S. B., Jones W. G., Keizer J., van Oosterom A. T., Meyer S., Vendrik C. P. Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer. 1991;27(6):695–698. doi: 10.1016/0277-5379(91)90168-d. [DOI] [PubMed] [Google Scholar]
  22. Jeziorska M., Haboubi N. Y., Schofield P. F., Ogata Y., Nagase H., Woolley D. E. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colorectal Dis. 1994 Aug;9(3):141–148. doi: 10.1007/BF00290191. [DOI] [PubMed] [Google Scholar]
  23. Lobb R. R., Key M. E., Alderman E. M., Fett J. W. Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. Int J Cancer. 1985 Oct 15;36(4):473–478. doi: 10.1002/ijc.2910360410. [DOI] [PubMed] [Google Scholar]
  24. Logothetis C. J., Samuels M. L., Trindade A., Johnson D. E. The growing teratoma syndrome. Cancer. 1982 Oct 15;50(8):1629–1635. doi: 10.1002/1097-0142(19821015)50:8<1629::aid-cncr2820500828>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  25. McDonnell S., Navre M., Coffey R. J., Jr, Matrisian L. M. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4(6):527–533. doi: 10.1002/mc.2940040617. [DOI] [PubMed] [Google Scholar]
  26. Mead G. M., Stenning S. P., Parkinson M. C., Horwich A., Fossa S. D., Wilkinson P. M., Kaye S. B., Newlands E. S., Cook P. A. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol. 1992 Jan;10(1):85–94. doi: 10.1200/JCO.1992.10.1.85. [DOI] [PubMed] [Google Scholar]
  27. Mulders P. F., Oosterhof G. O., Boetes C., de Mulder P. H., Theeuwes A. G., Debruyne F. M. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol. 1990 Oct;66(4):425–429. doi: 10.1111/j.1464-410x.1990.tb14967.x. [DOI] [PubMed] [Google Scholar]
  28. Newell K. J., Witty J. P., Rodgers W. H., Matrisian L. M. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog. 1994 Aug;10(4):199–206. doi: 10.1002/mc.2940100404. [DOI] [PubMed] [Google Scholar]
  29. Nijman J. M., Schraffordt Koops H., Kremer J., Sleijfer D. T. Gonadal function after surgery and chemotherapy in men with stage II and III nonseminomatous testicular tumors. J Clin Oncol. 1987 Apr;5(4):651–656. doi: 10.1200/JCO.1987.5.4.651. [DOI] [PubMed] [Google Scholar]
  30. Porte H., Chastre E., Prevot S., Nordlinger B., Empereur S., Basset P., Chambon P., Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer. 1995 Feb 20;64(1):70–75. doi: 10.1002/ijc.2910640114. [DOI] [PubMed] [Google Scholar]
  31. Poulsom R., Pignatelli M., Stetler-Stevenson W. G., Liotta L. A., Wright P. A., Jeffery R. E., Longcroft J. M., Rogers L., Stamp G. W. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 1992 Aug;141(2):389–396. [PMC free article] [PubMed] [Google Scholar]
  32. Ransohoff D. F., Feinstein A. R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978 Oct 26;299(17):926–930. doi: 10.1056/NEJM197810262991705. [DOI] [PubMed] [Google Scholar]
  33. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25;219(4587):983–985. doi: 10.1126/science.6823562. [DOI] [PubMed] [Google Scholar]
  34. Senger D. R., Perruzzi C. A., Feder J., Dvorak H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986 Nov;46(11):5629–5632. [PubMed] [Google Scholar]
  35. Steyerberg E. W., Keizer H. J., Fosså S. D., Sleijfer D. T., Toner G. C., Schraffordt Koops H., Mulders P. F., Messemer J. E., Ney K., Donohue J. P. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995 May;13(5):1177–1187. doi: 10.1200/JCO.1995.13.5.1177. [DOI] [PubMed] [Google Scholar]
  36. Steyerberg E. W., Keizer H. J., Stoter G., Habbema J. D. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer. 1994;30A(9):1231–1239. doi: 10.1016/0959-8049(94)90164-3. [DOI] [PubMed] [Google Scholar]
  37. Steyerberg E. W., Keizer H. J., Zwartendijk J., Van Rijk G. L., Van Groeningen C. J., Habbema J. D., Stoter G. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer. 1993 Jul;68(1):195–200. doi: 10.1038/bjc.1993.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tait D., Peckham M. J., Hendry W. F., Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984 Nov;50(5):601–609. doi: 10.1038/bjc.1984.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., Brown P. D., Giavazzi R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995 Feb 15;87(4):293–298. doi: 10.1093/jnci/87.4.293. [DOI] [PubMed] [Google Scholar]
  40. Toner G. C., Panicek D. M., Heelan R. T., Geller N. L., Lin S. Y., Bajorin D., Motzer R. J., Scher H. I., Herr H. W., Morse M. J. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990 Oct;8(10):1683–1694. doi: 10.1200/JCO.1990.8.10.1683. [DOI] [PubMed] [Google Scholar]
  41. Wang X., Fu X., Brown P. D., Crimmin M. J., Hoffman R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726–4728. [PubMed] [Google Scholar]
  42. Watson S. A., Morris T. M., Crosbee D. M., Hardcastle J. D. A hepatic invasive human colorectal xenograft model. Eur J Cancer. 1993;29A(12):1740–1745. doi: 10.1016/0959-8049(93)90117-x. [DOI] [PubMed] [Google Scholar]
  43. Watson S. A., Morris T. M., Robinson G., Crimmin M. J., Brown P. D., Hardcastle J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 1995 Aug 15;55(16):3629–3633. [PubMed] [Google Scholar]
  44. Zucker S., Lysik R. M., Zarrabi M. H., Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993 Jan 1;53(1):140–146. [PubMed] [Google Scholar]
  45. van der Schouw Y. T., Straatman H., Verbeek A. L. ROC curves and the areas under them for dichotomized tests: empirical findings for logistically and normally distributed diagnostic test results. Med Decis Making. 1994 Oct-Dec;14(4):374–381. doi: 10.1177/0272989X9401400408. [DOI] [PubMed] [Google Scholar]
  46. van der Stappen J. W., Hendriks T., Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer. 1990 Jun 15;45(6):1071–1078. doi: 10.1002/ijc.2910450616. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES